Investment Analysts’ Weekly Ratings Updates for Viridian Therapeutics (VRDN)

Several brokerages have updated their recommendations and price targets on shares of Viridian Therapeutics (NASDAQ: VRDN) in the last few weeks:

• 5/7/2025 – Viridian Therapeutics had its price target lowered by analysts at Royal Bank of Canada from $46.00 to $45.00. They now have an “outperform” rating on the stock.
• 5/7/2025 – Viridian Therapeutics had its price target lowered by analysts at JMP Securities from $42.00 to $38.00. They now have a “market outperform” rating on the stock.
• 5/7/2025 – Viridian Therapeutics had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $31.00 to $27.00. They now have a “buy” rating on the stock.
• 5/7/2025 – Viridian Therapeutics had its price target lowered by analysts at Needham & Company LLC from $38.00 to $36.00. They now have a “buy” rating on the stock.
• 4/23/2025 – Viridian Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $34.00 price target on the stock.

Viridian Therapeutics Price Performance

Shares of NASDAQ:VRDN opened at $12.94 on Monday. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. Viridian Therapeutics, Inc. has a 1-year low of $9.90 and a 1-year high of $27.20. The company has a market capitalization of $1.06 billion, a P/E ratio of -3.00 and a beta of 0.57. The firm’s 50 day simple moving average is $13.41 and its two-hundred day simple moving average is $17.10.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.08. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.16 million. The business’s quarterly revenue was up .0% compared to the same quarter last year. Research analysts expect that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Hedge Funds Weigh In On Viridian Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Exome Asset Management LLC purchased a new position in Viridian Therapeutics during the first quarter valued at approximately $2,929,000. Goldman Sachs Group Inc. lifted its holdings in shares of Viridian Therapeutics by 33.8% in the first quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after buying an additional 310,998 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Viridian Therapeutics by 1.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock worth $669,000 after buying an additional 876 shares in the last quarter. ADAR1 Capital Management LLC lifted its holdings in shares of Viridian Therapeutics by 203.8% in the first quarter. ADAR1 Capital Management LLC now owns 79,000 shares of the company’s stock worth $1,065,000 after buying an additional 53,000 shares in the last quarter. Finally, Maverick Capital Ltd. lifted its holdings in shares of Viridian Therapeutics by 0.4% in the first quarter. Maverick Capital Ltd. now owns 2,061,274 shares of the company’s stock worth $27,786,000 after buying an additional 7,368 shares in the last quarter.

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.